Tendencias de la evidencia científica de las evaluaciones económicas y las enfermedades no transmisibles: un análisis bibliométrico

  • Astrid Lorena Cubillos Osorio Pontificia Universidad Javeriana
  • Francisco Palencia Sánchez Pontificia Universidad Javeriana
  • Martha Riaño Casallas Universidad Nacional de Colombia
Palabras clave: evaluación económica, enfermedades no transmisibles, costos y análisis de costo, carga global de enfermedades

Resumen

el envejecimiento de la población a nivel global ha generado un creciente interés en el estudio de las Enfermedades No Transmisibles (ENT) y la necesidad de evaluar económicamente su abordaje, dado su impacto en la mortalidad. El objetivo de este estudio es analizar la producción científica de evaluaciones económicas de las ENT y detectar áreas de investigación menos exploradas. Se llevó a cabo una búsqueda de la literatura en Web of Science (WoS), PubMed y Scopus. Se utilizó R/Bibliometrix y VosViewer para el análisis de datos. Los resultados revelaron un incremento en la producción científica a lo largo del tiempo. La revista “Value in Health” se destacó por ser la que más publicaciones ha realizado y los autores Mark Lamotte y Lieven Annemans fueron los que más publicaron. Los principales nodos de información estuvieron relacionados con diabetes en las ENT y con carga de enfermedad y costo-efectividad en las evaluaciones económicas. En conclusión, la producción científica relacionada con las evaluaciones económicas de las ENT se enfoca predominantemente en el análisis de los costos directos asociados a estas enfermedades y a los subanálisis de los Estudios de la Carga Global de Enfermedad.

Biografía del autor/a

Astrid Lorena Cubillos Osorio, Pontificia Universidad Javeriana

Residente Medicina Familiar, Mg. epidemiología, MD. Pontificia Universidad Javeriana, Bogotá, Colombia.

Francisco Palencia Sánchez, Pontificia Universidad Javeriana

Doctor en Salud Pública, Mg. Epidemiología clínica, MD. Profesor Facultad de Medicina. Pontificia Universidad Javeriana. Bogotá, Colombia.

Martha Riaño Casallas, Universidad Nacional de Colombia

Doctora en Ciencias Económicas, Mg. en Salud y Seguridad en el Trabajo, Administradora de Empresas. Profesora Asociada Facultad de Ciencias Económicas, Universidad Nacional de Colombia. Bogotá, Colombia.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Astrid Lorena Cubillos Osorio, Pontificia Universidad Javeriana

Residente Medicina Familiar, Mg. epidemiología, MD. Pontificia Universidad Javeriana, Bogotá, Colombia.

Francisco Palencia Sánchez, Pontificia Universidad Javeriana

Doctor en Salud Pública, Mg. Epidemiología clínica, MD. Profesor Facultad de Medicina. Pontificia Universidad Javeriana. Bogotá, Colombia.

Martha Riaño Casallas, Universidad Nacional de Colombia

Doctora en Ciencias Económicas, Mg. en Salud y Seguridad en el Trabajo, Administradora de Empresas. Profesora Asociada Facultad de Ciencias Económicas, Universidad Nacional de Colombia. Bogotá, Colombia.

Referencias bibliográficas

United Nations, Department of Economic and Social Affairs. World Population Prospects 2019: Highlights. Disponible en: https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf

Vollset SE, et al. Fertility, Mortality, Migration, and Population Scenarios for 195 Countries and Territories from 2017 to 2100: A Forecasting Analysis for the Global Burden of Disease Study. The Lancet. [Internet].2020;396(10258):1285-306.https://doi.org/10.1016/S0140-6736(20)30677-2

Scott AJ. The Longevity Society. The Lancet Healthy Longevity [Internet]. 2021;2(12):e820-7. https://doi.org/10.1016/S2666-7568(21)00247-6

World Health Organization. The top 10 Causes of Death [Visitada en 2022 Enero 23]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

Etienne CF. Promover la información sobre la economía de las enfermedades no transmisibles en la Región de las Américas*. Rev Panam Salud Publica.[Internet]. 2018 Jun;42:e94. https://doi.org/10.26633/RPSP.2018.94

Dang A, Likhar N, Alok U. Importance of Economic Evaluation in Health Care: An Indian Perspective.Value Health Reg Issues. [Internet]. 2016 May;9:78-83.https://doi.org/10.1016/j.vhri.2015.11.005

Ruiz A, Morillo L. Epidemiología clínica: investigación clínica aplicada. Bogotá: Editorial Médica Panamericana;2004.

Yousefi M, et al. Household Health Costs: Direct, Indirect, and Intangible. Iran J Public Health. [Internet].2014 Feb;43(2):202-209. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450688/

Donthu N, et al. How to Conduct a Bibliometric Analysis: An Overview and Guidelines. J Bus Res. [Internet].2021Sep;133:285-96. https://doi.org/10.1016/j.jbusres.2021.04.070

Van Eck NJ, Waltman L. Software Survey: VOSviewer,a Computer Program for Bibliometric Mapping. Scientometrics.[Internet]. 2010;84(2):523-538. https://doi.org/10.1007/s11192-009-0146-3

Salinas DT. Bibliometrix: Primeros pasos y técnicas avanzadas con BiblioShiny App. Zenodo; 2020.

Aria M, Cuccurullo C. Bibliometrix: An R-tool for Comprehensive Science Mapping Analysis. J Informetr.[Internet]. 2017 Nov;11(4):959-75. https://doi.org/10.1016/j.joi.2017.08.007

Mulugeta W, et al. Disease Burdens and Risk Factors for Diabetes, Hypertension, and Hyperlipidemia among Refugees in Buffalo, New York, 2004-2014. J Health Care Poor Underserved. [Internet]. 2019;30(3):1119-1131. https://doi.org/10.1353/hpu.2019.0077

Park J, et al. High Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries with Diabetes,1999-2017. Diabetes Care. [Internet]. 2021;44(8):1797-1804. https://doi.org/10.2337/dc20-2708

Wang Y, et al. National Trends in Out-of-Pocket Costs Among U.S. Adults with Diabetes Aged 18-64 Years:2001-2017. Diabetes Care. [Internet]. 2021;44(11):2510-2517. https://doi.org/10.2337/dc20-2833

Wang H, et al. Cost-utility of Afatinib and Gefitinib as First-Line Treatment for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Future Oncol. [Internet]. 2019;15(2):181-191. https://doi.org/10.2217/fon-2018-0692

Wang Y, et al. Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US. Front Public Health. [Internet].2021;9:650392. https://doi.org/10.3389/fpubh.2021.650392

Wimo A, et al. An Economic Evaluation of Donepezil in Mild to moderate Alzheimer’s Disease: Results of a 1-year, Double-Blind, Randomized Trial [published correction appears in Dement Geriatr Cogn Disord. 2003;16(2):102]. Dement Geriatr Cogn Disord. [Internet]. 2003;15(1):44-54. https://doi.org/10.1159/000066669

Wimo A, et al. Resource Utilization and Cost Analysi of Memantine in Patients with Moderate to Severe Alzheimer’s Disease. Pharmacoeconomics. [Internet].2003;21(5):327-340. https://doi.org/10.2165/00019053-200321050-00004

Handels RLH, et al. Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.J Alzheimers Dis. [Internet]. 2017;60(4):1477-1487. https://doi.org/10.3233/JAD-170324

Handels RLH, et al. Early Cost-Utility Analysis of General and Cerebrospinal Fluid-specific Alzheimer’s Disease Biomarkers for Hypothetical Disease-Modifying Treatment Decision in Mild Cognitive Impairment. Alzheimer’s & Dementia [Internet]. 2015;11(8):896-905. https://doi.org/10.1016/j.jalz.2015.02.009

Vossius C, et al. Cost Analysis of Day Care Centres in Norway. PLoS One. [Internet]. 2019 Ago 8;14(8):e0219568. https://doi.org/10.1371/journal.pone.0219568

Wimo A, et al. Cost-utility Analysis of Group Living in Dementia Care. Int J Technol Assess Health Care.[Internet]. 1995;11(1):49-65. https://doi.org/10.1017/s0266462300005250

Robles-Zurita JA, et al. Economic Evaluation of Culprit Lesion only PCI vs. immediate Multivessel PCI in Acute Myocardial Infarction Complicated by Cardiogenic Shock: the Culprit-Shock Trial. Eur J Health Econ. [Internet]. 2020;21(8):1197-1209.https://doi.org/10.1007/s10198-020-01235-3

Wolowacz S, et al. Development and Validation of a Cost-Utility Model for Type 1 Diabetes Mellitus. Diabet Med. [Internet]. 2015;32(8):1023-1035. https://doi.org/10.1111/dme.12663

Cooper JT, et al. Health Related Quality of Life Utility Weights for Economic Evaluation through Different Stages of Chronic Kidney Disease: a Systematic Literature Review. Health Qual Life Outcomes. [Internet]. 2020 Sep 21;18(1):310.https://doi.org/10.1186/s12955-020-01559-x

Xin Y, et al. Type 2 Diabetes Remission: Economic Evaluation of the DiRECT/Counterweight-Plus Weight Management Programme within a Primary Care Randomized Controlled Trial. Diabet Med. [Internet].2019;36(8):1003-1012.https://doi.org/10.1111/dme.13981

Lamotte M, et al. A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease. Pharmacoeconomics. [Internet]. 2006;24(2):155-169. https://doi.org/10.2165/00019053-200624020-00005

Annemans L, et al. Health Economic Evaluation of Controlled and Maintained Physical Exercise in the Prevention of Cardiovascular and other Prosperity Diseases. Eur J Cardiovasc Prev Rehabil. [Internet].2007;14(6):815-824. https://doi.org/10.1097/HJR.0b013e3282ef514f

Tsutani K, et al. A Health Economic Evaluation of Aspirin in the Primary Prevention of Cardiovascular Disease in Japan. Intern Med. [Internet].2007;46(4):157-162. https://doi.org/10.2169/internalmedicine.46.1843

Wilson K, et al. An Economic Evaluation based on a Randomized Placebo-Controlled Trial of Varenicline in Smokers with Cardiovascular Disease: Results for Belgium, Spain, Portugal, and Italy. Eur J Prev Cardiol. [Internet]. 2012;19(5):1173-1183. https://doi.org/10.1177/1741826711420345

Kotseva K, et al. Patient and Caregiver Productivity Loss and Indirect Costs Associated with Cardiovascular Events in Europe. Eur J Prev Cardiol.[Internet]. 2019;26(11):1150-1157. https://doi.org/10.1177/2047487319834770

GBD 2017 DALYs and HALE Collaborators. Global,Regional, and National Disability-Adjusted Life-Years (DALYs) for 359 Diseases and Injuries and HealthyLife Expectancy (HALE) for 195 Countries and Territories,1990-2017: A Systematic Analysis for the Global

Burden of Disease Study 2017 [published correction appears in Lancet. 2019 Jun 22;393(10190):e44]. Lancet.[Internet]. 2018;392(10159):1859-1922. https://doi.org/10.1016/S0140-6736(18)32335-3

Theodoratou D, et al. Analysis of Published Economic Evaluations of Angiotensin Receptor Blockers. Hellenic J Cardiol. [Internet]. 2009 Mar-Abr;50(2):105-118.Disponible en: https://pubmed.ncbi.nlm.nih.gov/19329412/

Maniadakis N, et al. Economic Evaluation of Irbesartan in Combination with Hydrochlorothiazide in the Treatment of Hypertension in Greece. Eur J Health Econ. [Internet]. 2011;12(3):253-261. https://doi.org/10.1007/s10198-010-0243-5

Fragoulakis V, Kourlaba G, Maniadakis N. Economic Evaluation of Statins in High-risk Patients Treated for Primary and Secondary Prevention of Cardiovascular Disease in Greece. Clinicoecon Outcomes Res. [Internet]. 2012;4:135-143. https://doi.org/10.2147/CEOR.S31376

Palmer AJ, et al. Cost-effectiveness of Detemir-Based Basal/Bolus Therapy versus NPH-based Basal/Bolus Therapy for Type 1 diabetes in a UK Setting:An Economic Analysis Based on Meta-Analysis Results of four Clinical Trials. Curr Med Res Opin.[Internet]. 2004;20(11):1729-1746. https://doi.org/10.1185/030079904X5661

Sivignon M, et al. Health-economic Evaluation of Lung Cancer Drugs: do s and don ts in France. Value in Health. [Internet]. 2019; 22:S455. https://doi.org/10.1016/j.jval.2019.09.297

Lamotte M, et al. A Health Economic Evaluation of Concomitant Surgical Ablation for Atrial Fibrillation.Eur J Cardiothorac Surg. [Internet]. 2007;32(5):702-710. https://doi.org/10.1016/j.ejcts.2007.07.027

GBD 2017 DALYs and HALE Collaborators. Global,Regional, and National Disability-Adjusted Life-Years (DALYs) for 359 Diseases and Injuries and Healthy Life Expectancy (HALE) for 195 Countries And Territories,1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2019 Jun 22;393(10190):e44]. Lancet.[Internet].2018;392(10159):1859-1922. https://doi.org/10.1016/S0140-6736(18)32335-3

GBD 2013 DALYs and HALE Collaborators. Global, Regional, and National Disability-Adjusted Life-Years (DALYs) for 306 Diseases and Injuries and Healthy Life Expectancy (HALE) for 188 countries, 1990-2013: Quantifying the Epidemiological Transition. Lancet.[Internet]. 2015;386(10009):2145-2191. https://doi.org/10.1016/S0140-6736(15)61340-X

GBD 2015 DALYs and HALE Collaborators. Global,Regional, and National Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE), 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet. 2017 Jan 7;389(10064):e1].Lancet. [Internet]. 2016;388(10053):1603-1658. Diseases and Injuries and Healthy Life Expectancy https://doi.org/10.1016/S0140-6736(16)31460-X

GBD 2015 DALYs and HALE Collaborators. Global,Regional, and National Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE), 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet. 2017 Jan 7;389(10064):e1].Lancet. [Internet]. 2016;388(10053):1603-1658.https://doi.org/10.1016/S0140-6736(16)31460-X

Murray CJ, et al. Disability-adjusted Life Years (DALYs) for 291 Diseases and Injuries in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010 [published correction appears in Lancet.[Internet]. 2013; 380(9859):2197-2223. https://doi.org/10.1016/S0140-6736(12)61689-4

Aghaei Chadegani A, et al. A Comparison Between two Main Academic Literature Collections: Web of Science and Scopus Databases. Asian Social Science [Internet]. 2013;9(5):18-26. https://doi.org/10.5539/ass.v9n5p18

Zhu J, Liu W. A Tale of two Databases: the use of Web of Science and Scopus in Academic Papers. Scientometrics.[Internet]. 2020;123(1):321-35. https://doi.org/10.1007/s11192-020-03387-8

National Center for Biotechnology information (NCBI). National Library of Medicine. PubMed [Visitada en 2022 Jul 3]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/

Palmer AJ, et al. An Economic Evaluation of Irbesartan in the Treatment of Patients with type 2 Diabetes, Hypertension and Nephropathy: Cost-Effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant. [Internet]. 2003;18(10):2059-2066. https://doi.org/10.1093/ndt/gfg232

World University Rankings. QS World University Rankings 2022: Top Global Universities | Top Universities. 2022. [Visitada en 2022 Jul 3]. Disponible en: https://www.topuniversities.com/university-rankings/world-university-rankings/2022

Muñoz PAE, Casallas MIR. Relación entre felicidad en el trabajo y desempeño laboral: análisis bibliométrico, evolución y tendencias. Revista Virtual Universidad Católica del Norte. [Internet]. 2021;(64):241-80. https://doi.org/10.35575/rvucn.n64a10

Cómo citar
Cubillos Osorio, A. L., Palencia Sánchez, F., & Riaño Casallas, M. (2023). Tendencias de la evidencia científica de las evaluaciones económicas y las enfermedades no transmisibles: un análisis bibliométrico. Revista Med, 31(1), 59–74. https://doi.org/10.18359/rmed.6408
Publicado
2023-12-29
Sección
Artículos

Métricas

Crossref Cited-by logo
QR Code